We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes
Webinar

Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes

Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes
Webinar

Multi-Modal Connected Workflow for Cardiac Safety Assessment of Drugs Using hiPSC-Derived Cardiomyocytes

Ryan McGarrigle
Ryan McGarrigle
Research Scientist, Agilent Technologies
Xiaoyu Zhang
Xiaoyu Zhang
Senior Research Scientist, Agilent Technologies
Pharmaceutical compounds need to undergo safety assessment screening. These in vitro frontline screening assays should be multi-parametric, scalable and mechanistic enabling a high degree of predictivity and specificity. Increasingly, cardiomyocytes are being utilized for the safety assessment of pharmaceutical compounds as they represent a highly relevant model system and can potentially provide broad information regarding electrical, mechanical, metabolic and structural liabilities.

In this webinar, we will discuss a connected workflow using human iPSC-derived cardiomyocytes (hiPSC-CMs) for microelectrode-based measurements (including viability and contraction, live-cell imaging, mitochondrial toxicity, and cell metabolism) as a frontline screening assay for safety assessment of pharmaceutical drug compounds. 

Attend this webinar to:
  • Learn about technologies for studying viability, contractility, electrophysiology, and metabolism of cardiomyocytes
  • Gain a deeper understanding of in vitro cardiotoxicity screening strategy
  • How to extract relevant information on adverse effects of drug from the same cell preparation
Advertisement